Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
about
Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonistDisc in flames: Roles of TNF-α and IL-1β in intervertebral disc degenerationClinical significance of tumor necrosis factor-α inhibitors in the treatment of sciatica: a systematic review and meta-analysisRole of cytokines in intervertebral disc degeneration: pain and disc contentEmerging technologies for molecular therapy for intervertebral disk degenerationDevelopments in intervertebral disc disease research: pathophysiology, mechanobiology, and therapeuticsEvaluation of metabolic syndrome in patients with chronic low back pain: using the fourth Korea national health and nutrition examination survey data.Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept studyInfluence of cytokine inhibitors on concentration and activity of MMP-1 and MMP-3 in disc herniationTNF is required for the induction but not the maintenance of compression-induced BME signals in murine tail vertebrae: limitations of anti-TNF therapy for degenerative disc diseaseInflammation in intervertebral disc degeneration and regenerationUpdated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007A systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciaticaImmunotherapy targeting cytokines in neuropathic pain.TNF-alpha and neuropathic pain--a review.Etanercept: an introduction.Perispinal etanercept: a new therapeutic paradigm in neurology.Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-α.Disease-modifying Antirheumatic Drugs for the Treatment of Low Back Pain: A Systematic Review of the Literature.Combination of two cytokine inhibitors reduces nucleus pulposus-induced nerve injury more than using each inhibitor separately.Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.Gait abnormalities and inflammatory cytokines in an autologous nucleus pulposus model of radiculopathy.An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration.Radiculopathy associated with disc herniation.Attenuation of inflammatory events in human intervertebral disc cells with a tumor necrosis factor antagonist.Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier.P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis.Antiallodynic and antihyperalgesic activities of zerumbone via the suppression of IL-1β, IL-6, and TNF-α in a mouse model of neuropathic pain.Progranulin derived engineered protein Atsttrin suppresses TNF-α-mediated inflammation in intervertebral disc degenerative disease.Evaluation of metabolic syndrome in patients with chronic low back pain.Targeting cytokines for treatment of neuropathic pain.[Biotechnological therapies for the treatment of back pain: alternatives to corticosteroids].
P2860
Q24656182-AB61FB42-9A05-40C8-AE56-9E60EB412BB0Q26783031-A44C2B70-15E7-42C1-B797-D6325407799BQ26851231-3EFEB386-D32A-4FA4-99E3-455CF1B446C1Q27001658-53A085DE-9207-4BAF-8DED-E1560B2E3DEBQ27693848-25285BD6-B67D-41AC-BD3E-BB7AF83C4F50Q28390520-6A14F437-23C2-4347-9907-F7527CF5DF9CQ34128499-B38403C3-3FD5-4C50-B0C4-F9EFBF56B07CQ34140663-2438B086-0F05-4914-9B03-B543F6AD2B55Q34413252-0DF545EF-148A-4224-ABBE-E77DF7D621A3Q34794168-20D24DFE-6E5E-42BE-8A6E-0108FC2AE0ACQ35134360-D67EEFD1-005A-4607-9407-D189C628B78EQ35579517-2117D36A-91E0-4C2E-AF06-4A4F32865EAEQ36171750-4A3B4CA6-3B55-4431-ACF2-06083FD292C1Q37182480-12D5CF31-8B1A-4953-8301-292372C95DFAQ37334025-BE2E5F7A-7781-4762-B3D4-F90B9B81091AQ37732472-A72811B1-7247-4909-AAF0-F4C135F76AECQ37754607-112B3270-B2D2-4340-A134-64ACADC61DB0Q37762260-3009E9F1-D2EC-45F3-9591-A0F25A7064D0Q37931781-3AE275FC-E92B-477A-949B-0BF4C93B19B5Q38511512-C05A586B-D4E1-4951-8DF3-7B03C6CA21C4Q39749602-103D5C1C-D863-4EF9-BEB6-3181AC611B25Q39906629-934D3D88-C1A0-4F90-8E84-462C7F71FCC2Q39991041-5E12035C-ACAD-45DE-B560-9D8DA5605B44Q41791113-CED3137D-BE8E-45BE-BE40-7354B637EEA8Q41860761-D7F24A3D-F860-48B8-8822-C78DFD76B443Q42206619-D1E7059D-BBEC-4E4C-969E-933FB92BBEA9Q42559841-7DF23541-BF4F-4EB1-8848-B7565C0471AAQ43214803-7D583FEB-8187-4ECA-A5DA-B4AB835F86A6Q45789792-1EFD6AAD-8508-409C-8DE8-33C03928A01BQ47220337-2DC93958-CC72-482D-BAAD-A9C53DAF2B7DQ48951574-6566161E-391D-4537-BDFE-2BD21A6D2DDBQ49923328-0362F579-0ECA-4D68-9898-B4855CA89A93Q54646088-EC910844-3192-4D2D-A155-D9C107C4AB07
P2860
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
@ast
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
@en
type
label
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
@ast
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
@en
prefLabel
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
@ast
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
@en
P2860
P356
P1476
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study
@en
P2093
P2860
P304
P356
10.1136/ARD.2003.016451
P407
P577
2004-04-28T00:00:00Z